317 related articles for article (PubMed ID: 31492792)
21. A methodological approach for assessing the uptake of core outcome sets using ClinicalTrials.gov: findings from a review of randomised controlled trials of rheumatoid arthritis.
Kirkham JJ; Clarke M; Williamson PR
BMJ; 2017 May; 357():j2262. PubMed ID: 28515234
[No Abstract] [Full Text] [Related]
22. Value and usability of unpublished data sources for systematic reviews and network meta-analyses.
Halfpenny NJ; Quigley JM; Thompson JC; Scott DA
Evid Based Med; 2016 Dec; 21(6):208-213. PubMed ID: 27686328
[TBL] [Abstract][Full Text] [Related]
23. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
24. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
[TBL] [Abstract][Full Text] [Related]
25. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting.
Dekkers OM; Cevallos M; Bührer J; Poncet A; Ackermann Rau S; Perneger TV; Egger M
J Clin Epidemiol; 2015 May; 68(5):510-7. PubMed ID: 25450451
[TBL] [Abstract][Full Text] [Related]
26. Association of trial registration with the results and conclusions of published trials of new oncology drugs.
Rasmussen N; Lee K; Bero L
Trials; 2009 Dec; 10():116. PubMed ID: 20015404
[TBL] [Abstract][Full Text] [Related]
27. Association between trial registration and treatment effect estimates: a meta-epidemiological study.
Dechartres A; Ravaud P; Atal I; Riveros C; Boutron I
BMC Med; 2016 Jul; 14(1):100. PubMed ID: 27377062
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of the processes used to link clinical trial registrations to their published results.
Bashir R; Bourgeois FT; Dunn AG
Syst Rev; 2017 Jul; 6(1):123. PubMed ID: 28669351
[TBL] [Abstract][Full Text] [Related]
29. RReACT goes global: perils and pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results.
Munch T; Dufka FL; Greene K; Smith SM; Dworkin RH; Rowbotham MC
Pain; 2014 Jul; 155(7):1313-1317. PubMed ID: 24726925
[TBL] [Abstract][Full Text] [Related]
30. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials.
Perlmutter AS; Tran VT; Dechartres A; Ravaud P
Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448
[TBL] [Abstract][Full Text] [Related]
31. What happens to intimate partner violence studies registered on clinicaltrials.gov? A systematic review of a clinical trials registry.
Madden K; Tai K; Schneider P; Evaniew N; Ghert MA; Bhandari M
Trials; 2019 May; 20(1):288. PubMed ID: 31133073
[TBL] [Abstract][Full Text] [Related]
32. Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Lemmens CMC; van Amerongen S; Strijbis EM; Killestein J
Neurology; 2024 Mar; 102(6):e208032. PubMed ID: 38408286
[TBL] [Abstract][Full Text] [Related]
33. Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety?
Lv JW; Chen YP; Zhou GQ; Liu X; Guo Y; Mao YP; Ma J; Sun Y
J Natl Compr Canc Netw; 2017 Nov; 15(11):1363-1371. PubMed ID: 29118228
[No Abstract] [Full Text] [Related]
34. Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials.
Jones CW; Adams AC; Murphy E; King RP; Saracco B; Stesis KR; Cavanaugh S; Roberts BW; Platts-Mills TF
BMC Med Res Methodol; 2021 Jun; 21(1):120. PubMed ID: 34103009
[TBL] [Abstract][Full Text] [Related]
35. Comparison between publicly accessible publications, registries, and protocols of phase III trials indicated persistence of selective outcome reporting.
Zhang S; Liang F; Li W
J Clin Epidemiol; 2017 Nov; 91():87-94. PubMed ID: 28757260
[TBL] [Abstract][Full Text] [Related]
36. Differences in reporting serious adverse events in industry sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a cross-sectional study.
Hughes S; Cohen D; Jaggi R
BMJ Open; 2014 Jul; 4(7):e005535. PubMed ID: 25009136
[TBL] [Abstract][Full Text] [Related]
37. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
[TBL] [Abstract][Full Text] [Related]
38. Selective outcome reporting in randomized clinical trials of dental implants.
Sendyk DI; Rovai ES; Souza NV; Deboni MCZ; Pannuti CM
J Clin Periodontol; 2019 Jul; 46(7):758-765. PubMed ID: 31077411
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and knowledge synthesis approach for 456 network meta-analyses: a scoping review.
Zarin W; Veroniki AA; Nincic V; Vafaei A; Reynen E; Motiwala SS; Antony J; Sullivan SM; Rios P; Daly C; Ewusie J; Petropoulou M; Nikolakopoulou A; Chaimani A; Salanti G; Straus SE; Tricco AC
BMC Med; 2017 Jan; 15(1):3. PubMed ID: 28052774
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
